Shionogi & Co. announced plans to acquire IntraBio for $2 billion to expand its assets in rare diseases. The transaction is expected to close by year-end through Shionogi Inc.
Osaka-headquartered Shionogi & Co. will acquire IntraBio, which focuses on rare neurodegenerative diseases, for $2 billion upfront. The transaction is expected to close between November and December through Shionogi's New Jersey subsidiary.
IntraBio's net sales in 2025 were $67.9 million, reportedly representing approximately 19-fold growth from 2024. Aqneursa, which drove that growth, could become an approved treatment for ataxia-telangiectasia in 2026.
IntraBio's pipeline includes not only rare diseases such as GM2 gangliosidosis, but also a broad range of indications, including CACNA1A-related disorders, hereditary cerebellar ataxia, epilepsy, migraine and sleep disorders. Shionogi is expected to seek to expand its scale by using its global commercial infrastructure, with the aim of strengthening its commercial assets in this area.
This week also saw coverage of developments at other companies, including Vaxcyte's VAX31, while Spain's biotechnology industry continues to face both the challenge of building capital depth and that of forming industrial clusters. Regulatory and policy developments in the United States and China are also described as affecting the investment environment.